Overview
Axiom Bio provides an AI-driven platform for predictive toxicology that helps drug researchers identify potential liver toxicity early in development. The platform uses a large proprietary dataset—over 115,000 small molecules screened on primary human liver cells with imaging and biochemical readouts, plus PK and clinical data—to predict drug-induced liver injury and related toxicity pathways from a molecule’s structure. It differentiates itself through its large human-toxicity dataset and by offering mechanistic insights (such as mitochondrial toxicity, ER stress, and ROS) at a low per-molecule cost. The goal is to speed up safe drug development by de-risking preclinical pipelines and reducing reliance on animal testing.
Work here?Claim your company
Simplify's take
What believers are saying
- GeneFab partnership on September 15, 2026 expands manufacturing and clinical-development execution.
- Google highlighted Axiom on November 10, 2026 as Carbon's leading translational-science benchmark.
- Axiom's 2026 public push and community round widen distribution before larger pharma pilots.
What critics are saying
- Axiom Bio opened a Wefunder round on November 12, 2026, signaling capital strain.
- Its July 2026 Hong Kong IPO push exposes weak U.S. financing and execution risk.
- Frontier models like Google Gemini Carbon already outperform Axiom on translational science tasks.
What makes Axiom Bio unique
- Axiom Bio built a proprietary 115,000-molecule human hepatocyte toxicity dataset by 2026.
- Its models connect cellular imaging, biochemical readouts, PK, and clinical outcomes.
- It focuses first on hepatotoxicity, the costliest, fastest-failing drug-development safety problem.
Help us improve and share your feedback! Did you find this helpful?